Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference
Royalty Pharma (Nasdaq: RPRX) has announced its upcoming participation in TD Cowen's 45th Annual Health Care Conference. The company will engage in a fireside chat scheduled for March 4, 2025, at 2:30 p.m. ET.
Interested parties can access the webcast through the company's 'Events' page on their investor relations website. The recording will remain available for a minimum of thirty days following the presentation.
Royalty Pharma (Nasdaq: RPRX) ha annunciato la sua prossima partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. L'azienda prenderà parte a una chiacchierata informale programmata per il 4 marzo 2025, alle 14:30 ET.
Le parti interessate possono accedere alla trasmissione in diretta tramite la pagina 'Eventi' del sito web delle relazioni con gli investitori dell'azienda. La registrazione sarà disponibile per un minimo di trenta giorni dopo la presentazione.
Royalty Pharma (Nasdaq: RPRX) ha anunciado su próxima participación en la 45ª Conferencia Anual de Salud de TD Cowen. La compañía participará en una charla informal programada para el 4 de marzo de 2025, a las 2:30 p.m. ET.
Las partes interesadas pueden acceder a la transmisión en vivo a través de la página de 'Eventos' en el sitio web de relaciones con inversores de la empresa. La grabación estará disponible durante un mínimo de treinta días después de la presentación.
Royalty Pharma (Nasdaq: RPRX)는 TD Cowen의 제45회 연례 헬스케어 컨퍼런스에 참가할 예정이라고 발표했습니다. 회사는 2025년 3월 4일 오후 2시 30분 ET에 예정된 대화에 참여할 것입니다.
관심 있는 분들은 회사의 투자자 관계 웹사이트의 '이벤트' 페이지를 통해 웹캐스트에 접속할 수 있습니다. 발표 후 최소 30일 동안 녹화본이 제공될 것입니다.
Royalty Pharma (Nasdaq: RPRX) a annoncé sa prochaine participation à la 45ème Conférence Annuelle sur la Santé de TD Cowen. L'entreprise participera à une discussion informelle prévue pour le 4 mars 2025, à 14h30 ET.
Les parties intéressées peuvent accéder au webinaire via la page 'Événements' sur le site web des relations investisseurs de l'entreprise. L'enregistrement sera disponible pendant un minimum de trente jours après la présentation.
Royalty Pharma (Nasdaq: RPRX) hat seine bevorstehende Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. Das Unternehmen wird an einem informellen Gespräch teilnehmen, das für den 4. März 2025, um 14:30 Uhr ET geplant ist.
Interessierte Parteien können über die 'Events'-Seite der Investor-Relations-Website des Unternehmens auf das Webcast zugreifen. Die Aufzeichnung wird mindestens dreißig Tage nach der Präsentation verfügbar sein.
- None.
- None.
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET.
The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 15 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
When is Royalty Pharma (RPRX) presenting at TD Cowen's Health Care Conference 2025?
How can investors watch Royalty Pharma's (RPRX) TD Cowen conference presentation?
How long will RPRX's TD Cowen conference webcast be available?
What type of presentation will RPRX deliver at the TD Cowen Healthcare Conference?
